Table 2 Microarray and RNA sequencing of dysregulated circRNAs in anticancer drug resistance
From: CircRNAs in anticancer drug resistance: recent advances and future potential
Cancer | Drug classes | Drug | Specimen | Methods | DEGs | Bioinformation analysis | Ref | |
|---|---|---|---|---|---|---|---|---|
UP | Down | |||||||
Prostate Cancer | Endocrine drugs | Enzalutamide | Enzalutamide resistance LNCaP cell models | Microarray | 278 | 588 | NA | [165] |
Breast Cancer | Tamoxifen | MCF7/TR and MCF7/P cells | RNA sequencing | 352 | 113 | NA | [172] | |
Anticancer antibiotics | Doxorubicin | MCF-7 and MCF-7/ADM cells | Microarray | 12 | 6 | MAPK and PI3K/Akt signaling pathway; | [117] | |
Acute Myeloid Leukemia | THP-1 and THP-1/ADM cells | Microarray | 35 | 14 | NA | [114] | ||
Pancreatic Cancer | Antimetabolite drugs | Gemcitabine | SWl990 and SWl990/GZ cells | Microarray | 26 | 55 | MAPK and mTOR signaling pathways; | [80] |
PANC-1 and PANC-1-GR cells | RNA sequencing | 68 | 58 | ErbB pathway; | [83] | |||
Colorectal Cancer | 5-FU | HCT116 and CRR-HCT116 cells | Microarray | 47 | 24 | Wnt signaling pathway; | [72] | |
Platinum drugs | Oxaliplatin | HCT116-P (parental) and HCT116-R cells | Microarray | 773 | 732 | Protein-binding activity; | [126] | |
Exosomes from HCT116-P (parental) and HCT116-R cells | Microarray | 105 | 34 | Longevity regulating pathway; Wnt signaling pathway; cGMP-PKG signaling pathway; | [127] | |||
Osteosarcoma | Cisplatin | Paired resistant and sensitive OS cell lines (MG63, KHOS and U2OS) | RNA sequencing | 57 | 23 | Glycosphingolipid biosynthesis–globo series; Linoleic acid metabolism; | [140] | |
Ovarian Cancer | Cisplatin-sensitive and cisplatin-resistant tissues | Microarray | 148 | 191 | NA | [156] | ||
Drugs derived from plants | Taxol | Taxol-sensitive and Taxol-resistant ovarian cancer tissues | Microarray | 341 | 492 | NA | [98] | |
NSCLC | A549 and A549/Taxol cells | Microarray | 2909 | 8372 | Small GTPase binding; Integrin signaling pathway; | [101] | ||
Targeted drug | Gefitinib | Plasma samples | Microarray | 989 | 388 | Biological processes of various cancers such as cancers of hematopoietic and lymphoid tissues, bladder cancer, colorectal cancer, and neuroblastoma; | [179] | |
Osimertinib | H1975/AZDR and H1975; HCC827/AZDR and HCC827; | Microarray | 7966 | 7538 | P53, mTOR, and focal adhesion signaling pathways; | [186] | ||